What happens to your weight when you stop a GLP-1

Key takeaways

• A year after semaglutide 2.4 mg was withdrawn, the 228 people in the STEP 1 extension who had been taking it had regained two-thirds of their loss. They ended 5.6 percent below their starting weight, after an observed 17.3 percent loss over the 68 weeks on treatment .
• STEP 4 randomized 803 people 2 to 1 after a 20-week run-in that took off 10.6 percent. Over the next 48 weeks the continued-semaglutide group lost another 7.9 percent while the switched-to-placebo group gained 6.9 percent, a 14.8 point gap on the primary treatment-policy estimand .
• SURMOUNT-4 randomized 670 people 1 to 1 after a 20.9 percent tirzepatide lead-in. Over the next 52 weeks those who continued lost a further 5.5 percent and those switched to placebo regained 14.0 percent, on the primary treatment-regimen estimand .
• Two 2026 trials tested alternatives to stopping outright. Dropping to 5 mg tirzepatide left people 16.6 percent below baseline at week 112 against 9.9 percent on placebo , and among plateaued participants switched to oral orforglipron, 74.7 percent of a prior tirzepatide weight loss was still held at week 52 against 49.2 percent on placebo .
• None of the withdrawal trials measured appetite, calorie intake or metabolic rate after the drug stopped. They measured weight and cardiometabolic markers . On the drug, a 60-week trial measured about 270 fewer calories eaten than placebo at a lab lunch at week 60 .

Skip to:

• Cost, side effects, hitting the goal: why people come off
• What the withdrawal trials actually found
• Why the weight comes back
• Most people do not end up back at their starting weight
• If you are thinking about stopping
• The bottom line

Cost, side effects, hitting the goal: why people come off

People stop GLP-1s for ordinary reasons. You hit the goal you set. The prescription gets too expensive, or your plan stops covering it, or the supply dries up for a few weeks. Or you are tired of the weekly shot and the gut side effects that come with it. The question is the same in every case: if you stop, does the weight come straight back?

The useful place to look is the small set of trials that ran the actual experiment: put people on a GLP-1, get them to a lower weight, then deliberately take the drug away and watch what happens next.

What the withdrawal trials actually found

The clearest picture comes from the STEP 1 extension, which followed 327 people for a year after treatment stopped. In the 228 of them who had been taking semaglutide (the drug in Wegovy and Ozempic), the observed average weight loss across the 68 treatment weeks was 17.3 percent. A year off the drug, they had regained two-thirds of that, landing 5.6 percent below where they started . So not all the way back, but most of the way.

Those extension analyses were exploratory, run descriptively on observed data from a subset of the trial . They give the shape of what happens after the drug stops rather than a precise forecast.

A second semaglutide trial, STEP 4, caught the split in real time. The 803 people who finished a 20-week run-in on the drug had lost 10.6 percent. They were then randomized 2 to 1: 535 kept taking semaglutide, 268 switched to placebo. Over the next 48 weeks the semaglutide group lost another 7.9 percent while the placebo group gained back 6.9 percent . The two groups had the same 20 weeks behind them and moved in opposite directions.

Those STEP 4 numbers come from the primary treatment-policy estimand, which counts everyone as randomized whether or not they stayed on the drug. The trial's secondary trial-product estimand, which models what would have happened had everyone kept taking their assigned treatment, puts it at minus 8.8 percent versus plus 6.5 percent . The direction is the same and the gap is slightly wider.

Tirzepatide (the drug in Mounjaro and Zepbound) tells the same story. In SURMOUNT-4, the 670 people who finished a 36-week lead-in had lost 20.9 percent, then were randomized 1 to 1 to continue or stop. Over the next 52 weeks those who kept going lost a further 5.5 percent. Those switched to placebo regained 14.0 percent, on the primary treatment-regimen estimand . The newer drug does not change the pattern.

A 2026 trial, ATTAIN-MAINTAIN, gives a third read. It took people who had been treated with tirzepatide or semaglutide in the SURMOUNT-5 trial and randomized them to the oral GLP-1 orforglipron or to placebo. Among those who had already plateaued, the placebo group held 49.2 percent of the tirzepatide-era loss and 37.6 percent of the semaglutide-era loss at week 52, against 74.7 and 79.3 percent on orforglipron .

That is roughly half the tirzepatide loss and nearly two-thirds of the semaglutide loss given back within a year of coming off the injectable. Even those figures are generous: from week 24, placebo participants who had regained half of what they lost were started on rescue orforglipron, and about 65 percent of that subgroup took it .

Why the weight comes back

The reason sits in what the drug was doing in the first place. A GLP-1 copies a gut hormone that regulates appetite and calorie intake, and the semaglutide label says semaglutide decreases calorie intake, likely by affecting appetite . That is the on-drug picture. While it is in your system, eating less is easier.

Eating has been measured on the drug. In a 60-week randomized trial, semaglutide participants ate about 270 fewer calories than placebo at a laboratory lunch at week 60, even though the groups no longer differed on subjective appetite ratings by weeks 40 and 60 . The calorie effect held while the felt appetite difference faded.

What happens to appetite after you stop has not been measured. STEP 1's extension, STEP 4 and SURMOUNT-4 all tracked body weight and cardiometabolic markers, not hunger, calorie intake or metabolic rate . Anyone quoting you a number for how much your appetite rebounds is going past the evidence. What the trials do show is the weight returning once the drug is gone.

Obesity behaves like a chronic condition. The semaglutide label describes the drug as something you use to reduce weight and keep it off long term , and the STEP 1 extension authors read their own results as evidence that obesity is chronic and that treatment probably has to continue for the weight and health gains to hold . The drug manages the condition. It does not cure it.

Most people do not end up back at their starting weight

The weight does tend to come back, and most people do not land all the way back at the start. In the STEP 1 extension, a full year off the drug, the average semaglutide participant was still 5.6 percent lighter than when they began . Those are averages, so some people regain almost everything and some hold onto a good chunk. Your result is not the trial mean.

STEP 4 and SURMOUNT-4 compared staying on the drug with coming off it, and neither tested how to stop and keep the loss . There is no taper schedule in the label to fall back on either: the semaglutide prescribing information carries a titration schedule for getting up to the maintenance dose and gives none for coming down .

One trial has now tested a middle option. SURMOUNT-MAINTAIN, published in 2026, ran 441 people through 60 weeks of weight loss on tirzepatide, then split the 378 who reached randomization three ways: stay at the maximum tolerated dose, drop to 5 mg, or switch to placebo for 52 weeks. At week 112 the maximum-dose group sat 21.9 percent below baseline, the 5 mg group 16.6 percent, and the placebo group 9.9 percent .

From week 84, anyone who had regained more than half of what they lost could be given rescue tirzepatide, so that 9.9 percent flatters what stopping outright does . A lower dose is also still ongoing treatment, and this is one Lilly-funded trial of 378 people. It shows a smaller dose holding more of the loss than placebo did. It is not a protocol for getting off.

The general habits behind any weight maintenance, enough protein, strength training, regular movement, are worth leaning on, but do not expect them to replace what the drug was doing. Anyone promising they will is selling something.

If you are thinking about stopping

Stopping is a normal decision, and cost, side effects, a reached goal or a pregnancy plan are each reason enough. If you stop, the trials say to expect the scale to drift up, so it is worth deciding in advance what you want to do about that instead of being blindsided three months later.

Whether to drop the dose instead of stopping, whether to switch products, what to watch for: that depends on your own history and what you were taking it for. And if a stalled plateau or rough side effects are what is pushing you toward quitting, those often have other fixes worth raising first.

The bottom line

Stopping a GLP-1 usually means giving back a large share of the weight, because the drug lowers appetite while you take it and that effect goes when the drug does. The withdrawal trials are consistent on this for both semaglutide and tirzepatide, and they frame these as long-term medications rather than a short course.

That is not a reason to never start, and it is not a reason to panic. It is a reason to know the number before you decide: two-thirds of the loss back within a year, in the trial that measured it .

For research and educational purposes only. Not medical advice.

pepSmart has not commissioned independent clinical review of this article.

More on how we write and source these pieces: Editorial process and contributor disclosure and Sourcing posture.

Spot an error? Email corrections via /about.

Sources: 7 entries, all primary canon (six peer-reviewed trial reports covering withdrawal, maintenance and on-treatment eating, plus the FDA prescribing information for semaglutide via DailyMed), last reviewed 2026-07-23.

Related tools

• Tirzepatide dose calculator - Run tirzepatide-focused vial draw math.
• GLP-1 conversion calculator - Convert a GLP-1 mg dose to U-100 units and ml.
• GLP-1 ramp planner - Preview a linear educational dose-step table.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
• PK simulator overview - Public overview of the Pro pharmacokinetic simulator.
• GLP-1 taper planner overview - Public overview of the Pro GLP-1 taper planner.